Short Interest in Iterum Therapeutics PLC (NASDAQ:ITRM) Declines By 21.2%

Iterum Therapeutics PLC (NASDAQ:ITRM) was the target of a significant drop in short interest in June. As of June 30th, there was short interest totalling 32,400 shares, a drop of 21.2% from the May 30th total of 41,100 shares. Based on an average trading volume of 7,300 shares, the short-interest ratio is presently 4.4 days. Approximately 0.8% of the company’s shares are short sold.

Shares of ITRM stock traded up $0.17 during trading on Friday, hitting $6.64. 1,200 shares of the company were exchanged, compared to its average volume of 10,067. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.36 and a quick ratio of 4.36. The company has a market capitalization of $88.37 million, a price-to-earnings ratio of -0.93 and a beta of 2.05. The business’s 50-day moving average is $6.69. Iterum Therapeutics has a twelve month low of $4.70 and a twelve month high of $11.22.

Iterum Therapeutics (NASDAQ:ITRM) last posted its earnings results on Tuesday, May 14th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.09). The business had revenue of $0.04 million during the quarter. Iterum Therapeutics had a negative net margin of 11,956.64% and a negative return on equity of 83.95%. On average, equities analysts predict that Iterum Therapeutics will post -6.43 earnings per share for the current year.

Several research analysts have recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and issued a $20.00 target price on shares of Iterum Therapeutics in a research report on Monday, March 25th. Royal Bank of Canada lifted their target price on shares of WestJet Airlines from C$20.00 to C$31.00 and gave the stock a “sector perform” rating in a research report on Wednesday, May 15th. Zacks Investment Research raised shares of Hudson Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday, May 29th. Finally, HC Wainwright restated a “buy” rating on shares of Interpace Diagnostics Group in a report on Friday, June 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $15.75.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Read More: What is a Lock-Up Period?

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with's FREE daily email newsletter.